Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778719 | 0.90 | PTGDR2 (0.57) | PTGDR2LATS1CCKARL3MBTL1 | |
| SCHEMBL1773016 | 0.86 | PTGDR2 (0.67) | PTGDR2CYP2C19LATS1HTR6CCKAR | |
| SCHEMBL5136369 | 0.83 | PTGDR2 (0.51) | PTGDR2METCYP2C19LATS1HTR6 | |
| SCHEMBL4583577 | 0.83 | PTGDR2 (0.64) | PTGDR2METCYP2C19LATS1HTR6 | |
| Formamide SCHEMBL28651025 | 0.80 | PTGDR2 (0.60) | PTGDR2CYP2C19LATS1HTR6CCKAR | |
| SCHEMBL19994702 | 0.79 | MET (0.50) | PTGDR2METCYP2C19HTR6L3MBTL1 | |
| SCHEMBL4583261 | 0.78 | PTGDR2 (0.51) | PTGDR2METCYP2C19LATS1HTR6 | |
| SCHEMBL15635129 | 0.78 | PTGDR2 (0.64) | PTGDR2CYP2C19LATS1HTR6CCKAR | |
| SCHEMBL30539171 | 0.77 | PTGDR2 (0.55) | PTGDR2LATS1CCKARL3MBTL1 | |
| SCHEMBL17827487 | 0.75 | PTGDR2 (0.63) | PTGDR2CYP2C19LATS1HTR6CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| EP-3515912-B1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| EP-3515912-B1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
| WO-2018055316-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | PSEN2, CLN6, MAPT | PTGDR2 1114/4885MET 4720/4885CYP2C19 3826/4885 |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | PSEN2, SNCA, MAPT | PTGDR2 1387/4885MET 4686/4885CYP2C19 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.